Dexmedetomidine for Reversal of Cocaine's Effects on the Heart

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

EARLY_PHASE1

Total Enrollment

115 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-02-01

Study Completion Date

2014-01-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will use myocardial contrast echocardiography performed during a continuous intravenous infusion of Definity microbubbles (Perflutren lipid microbubbles) to determine if dexmedetomidine (an intravenous central sympatholytic drug) can reverse all the cardiovascular effects of low-dose intranasal cocaine-including vasoconstriction in the coronary microcirculation-both in cocaine-naïve and non-treatment seeking cocaine-addicted subjects.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study to Improve Scientific Understanding of the Cardiovascular Actions of Cocaine

NCT00338546

Cocaine Induced Sympathoexciation and Vasoconstriction

WITHDRAWN PHASE1

Study to Assess Potential Interactions Between Intravenous Cocaine and Oral Lorcaserin

NCT02393599

Cocaine Abuse

COMPLETED PHASE1

The Effects of Doxazosin on the Cardiovascular and Subjective Effects of Cocaine

NCT01062945

Cocaine Addiction Cocaine Abuse Cocaine Dependence +1 more

COMPLETED PHASE1

Cognitive Enhancement and Relapse Prevention in Cocaine Addiction

NCT01067846

Cocaine Addiction

COMPLETED NA

DOX as a Potential Treatment for Methamphetamine Dependence

NCT02785393

Substance-Related Disorders

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Each subject will be participating in three study visits: Screening Visit, Visit 1: a low-dose dobutamine visit and Visit 2: a low-dose cocaine visit. At the dobutamine visit, the subject will only receive low-dose dobutamine, which will be used as an internal inotropic/vasodilator control for cocaine. At the cocaine visit, the subject will receive low-dose intranasal cocaine followed by either the active study drug (dexmedetomidine) or an inactive placebo (saline). Both cocaine and dobutamine will increase myocardial contractility and oxygen demand, thereby stimulating metabolic vasodilation. If, as predicted, cocaine also causes α-adrenergic agonist in the coronary microcirculation, then myocardial blood flow should increase less with cocaine then with dobutamine for a given level of myocardial oxygen demand. We will study if dexmedetomidine, a central sympatholytic, can normalize this cocaine effect. We previously have used dobutamine as a comparator for cocaine in our research. At both visits, myocardial contrast echocardiography will be used to measure regional myocardial perfusion.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chest Pain Acute Coronary Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Dexmedetomidine and intranasal cocaine

Intranasal cocaine administration (2 mg/kg) then Dexmedetomidine (0.3-0.6 mcg/kg) infusion

Group Type EXPERIMENTAL

Dexmedetomidine

Intervention Type DRUG

Dexmedetomidine (0.3-0.6 mcg/kg) infusion.

Intranasal cocaine

Intervention Type DRUG

Intranasal cocaine (2 mg/kg)

Normal saline and intranasal cocaine

Intranasal cocaine administration (2 mg/kg) then Saline (over 10 minutes I.V. infusion)

Group Type PLACEBO_COMPARATOR

Normal Saline

Intervention Type DRUG

Normal saline infusion (10 cc)

Intranasal cocaine

Intervention Type DRUG

Intranasal cocaine (2 mg/kg)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Dexmedetomidine

Dexmedetomidine (0.3-0.6 mcg/kg) infusion.

Intervention Type DRUG

Normal Saline

Normal saline infusion (10 cc)

Intervention Type DRUG

Intranasal cocaine

Intranasal cocaine (2 mg/kg)

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Precedex

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy adult subjects ages of 18-65 years without any history of substance abuse (other than tobacco), including narcotics, abuse of prescription painkillers, cocaine or any other recreational drug

Exclusion Criteria

* Known or suspected right-to-left, bi-directional, or transient right-to-left cardiac shunts or detected by screening echocardiogram performed prior to I.V. infusion of Definity microbubbles
* Hypersensitivity or prior reactions to Definity microbubbles
* Pregnant or nursing women
* Any evidence of cardiopulmonary disease by history or physical examination, including subjects who are taking any cardiovascular medications of any sort
* History of hypertension or BP at time of consent \> 140/90 mm Hg
* Any history of substance abuse (other than tobacco), including narcotics, prescription painkillers, cocaine or any other recreational drug (any person that says they have EVER tried these drugs will be excluded from this study)
* Subjects reporting alcohol intake of more than 2 drinks/day
* Severe psychiatric illness (e.g., schizophrenia, suicidal depression) in addition to drug dependence, which may signify a high risk of addiction
* Diabetes mellitus or any other systemic illness
* Individuals with a history of pseudocholinesterase deficiency
* Hypersensitivity to dexmedetomidine or lorazepam
* The presence of alcohol by breathalyzer
* Subjects who have poor echocardiography images will be screen failed.
* Persons with mechanically, magnetically, or electrically activated implants, such as cardiac pacemakers, neurostimulators, and infusion pumps (MRI only).
* Persons with ferromagnetic implants and ferromagnetic foreign bodies, such as intracranial, aneurysm clips, shrapnel and intraocular metal chips as these could become dislodged (MRI only).
* Persons unable to tolerate MRI imaging secondary to an inability to lie supine or severe claustrophobia (MRI only).
* Persons whose renal function test does not meet CSMC standard of care MRI contrast protocol requirements (GFR \<45ml/min).
* Persons with allergy to animal dander or animal-instigated asthma
* Persons with a history of kidney or liver disease.

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes